-transparent.png){kind=logo}
meta-Chlorophenylpiperazine (mCPP) is a non-selective 5-HT-receptor agonist/antagonist that is used extensively in psychiatry to assess central serotonergic function. We report on three patients who developed symptoms of the serotonin syndrome when they participated in an mCPP (0.5 mg/kg body weight p.o.) challenge test as part of a research protocol. They had relatively high plasma mCPP concentrations. The syndrome did not occur in normal volunteers who had comparable plasma concentrations of mCPP. Investigators should be aware of the possible occurrence of the serotonin syndrome after a single oral dose of mCPP.
Related Publications
T Klaassen, and
K L Ho Pian, and
H G Westenberg, and
J A den Boer, and
H M van Praag
September 1995,
Psychiatry research,
T Klaassen, and
K L Ho Pian, and
H G Westenberg, and
J A den Boer, and
H M van Praag
May 2000,
European journal of pharmacology,
T Klaassen, and
K L Ho Pian, and
H G Westenberg, and
J A den Boer, and
H M van Praag
October 2000,
European journal of pharmacology,
T Klaassen, and
K L Ho Pian, and
H G Westenberg, and
J A den Boer, and
H M van Praag
April 2004,
Journal of neurology,
T Klaassen, and
K L Ho Pian, and
H G Westenberg, and
J A den Boer, and
H M van Praag
January 1978,
Nihon rinsho. Japanese journal of clinical medicine,
T Klaassen, and
K L Ho Pian, and
H G Westenberg, and
J A den Boer, and
H M van Praag
June 1988,
Clinical pharmacology and therapeutics,
T Klaassen, and
K L Ho Pian, and
H G Westenberg, and
J A den Boer, and
H M van Praag
June 1988,
The Quarterly journal of medicine,
T Klaassen, and
K L Ho Pian, and
H G Westenberg, and
J A den Boer, and
H M van Praag
November 1995,
Neuroreport,
T Klaassen, and
K L Ho Pian, and
H G Westenberg, and
J A den Boer, and
H M van Praag
January 1987,
Clinical and experimental hypertension. Part A, Theory and practice,
T Klaassen, and
K L Ho Pian, and
H G Westenberg, and
J A den Boer, and
H M van Praag
August 1979,
Naunyn-Schmiedeberg's archives of pharmacology,
